
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision

<p xmlns="http://www.w3.org/1999/xhtml">
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ZLAB">ZLAB</a>, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,&#34; said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503 (IL-13/IL-31Rα), with a first-in-human data readout from the global Phase 1/1b study. The company is also preparing for the launch of COBENFY&#x2122; in China and for multiple anticipated regional regulatory approvals and expected data readouts.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Zai Lab</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ZLAB">ZLAB</a>, HKEX: 9688)) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

</p><p xmlns="http://www.w3.org/1999/xhtml">
For additional information about Zai Lab, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zailaboratory.com&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=www.zailaboratory.com&amp;index=1&amp;md5=2e4d44a60af99ac14977e8f5c0d0b0c3" shape="rect">www.zailaboratory.com</a> or follow us at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FZaiLab_Global&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FZaiLab_Global&amp;index=2&amp;md5=a7092bafe0417b0cf25ae2640d6f5133" shape="rect">https://x.com/ZaiLab_Global</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Zai Lab Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "poised," "positioned," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Our SEC filings can be found on our website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zailaboratory.com&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=www.zailaboratory.com&amp;index=3&amp;md5=4ac98eee4512a8f268eec5eb48e88c96" shape="rect">www.zailaboratory.com</a> and on the SEC's website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SEC.gov&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=www.SEC.gov&amp;index=4&amp;md5=03b3d913ed2e4ebe18ad3e09da948b92" shape="rect">www.SEC.gov</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260521314535r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260521314535/en/" rel="nofollow">https://www.businesswire.com/news/home/20260521314535/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">For more information, please contact:</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Christine Chiou / Cyan Liu
<br xmlns="http://www.w3.org/1999/xhtml"></br>+1 (917) 886-6929 / +86 195 3130 8895
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:christine.chiou1@zailaboratory.com" shape="rect">christine.chiou1@zailaboratory.com</a> / <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:cyan.liu@zailaboratory.com" shape="rect">cyan.liu@zailaboratory.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Shaun Maccoun / Xiaoyu Chen
<br xmlns="http://www.w3.org/1999/xhtml"></br>+1 (857) 270-8854 / +86 185 0015 5011
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:shaun.maccoun@zailaboratory.com" shape="rect">shaun.maccoun@zailaboratory.com</a> / <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:xiaoyu.chen@zailaboratory.com" shape="rect">xiaoyu.chen@zailaboratory.com</a>

</p>

ZLAB

Zai Lab Announces Changes to Senior Leadership Team

Zai Lab Implements Leadership Changes Amidst Key Drug Development Milestones

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Zai Lab has announced the departure of its President and COO to enhance operational performance. The company plans multiple clinical data readouts in 2026 for investigational therapies, which could significantly impact stock performance as they approach potential launches and approvals.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Zai Lab&#039;s President and COO Josh Smiley has departed, effective May 22.</li><li>The company aims for improved operational performance with leadership changes.</li><li>Zai Lab anticipates 2026 clinical readouts for lead therapies, potentially boosting stock.</li><li>Upcoming launch of COBENFY™ in China may enhance revenue streams.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Zai Lab Limited (ZLAB)</strong>: The leadership changes may impact operational direction amidst clinical trials.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments due to the significance of leadership changes impacting future performance and strategic direction.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Leadership changes may distract from execution if not managed well.</li><li>Successful clinical trial results in 2026 could dramatically increase ZLAB&#039;s valuation.</li><li>The launch of COBENFY™ in China is critical for short-term revenue growth.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Josh Smiley departed Zai Lab effective May 22.</li><li>Multiple clinical data readouts are anticipated in 2026.</li><li>Upcoming COBENFY™ launch is targeted for the Chinese market.</li><li>Zai Lab focuses on oncology, immunology, neuroscience, and infectious diseases.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a long position in ZLAB as clinical milestones loom in 2026.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ZLAB">ZLAB</a>, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,&#34; said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503 (IL-13/IL-31Rα), with a first-in-human data readout from the global Phase 1/1b study. The company is also preparing for the launch of COBENFY&#x2122; in China and for multiple anticipated regional regulatory approvals and expected data readouts.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Zai Lab</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ZLAB">ZLAB</a>, HKEX: 9688)) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

</p><p xmlns="http://www.w3.org/1999/xhtml">
For additional information about Zai Lab, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zailaboratory.com&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=www.zailaboratory.com&amp;index=1&amp;md5=2e4d44a60af99ac14977e8f5c0d0b0c3" shape="rect">www.zailaboratory.com</a> or follow us at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FZaiLab_Global&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FZaiLab_Global&amp;index=2&amp;md5=a7092bafe0417b0cf25ae2640d6f5133" shape="rect">https://x.com/ZaiLab_Global</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Zai Lab Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "poised," "positioned," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Our SEC filings can be found on our website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zailaboratory.com&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=www.zailaboratory.com&amp;index=3&amp;md5=4ac98eee4512a8f268eec5eb48e88c96" shape="rect">www.zailaboratory.com</a> and on the SEC's website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SEC.gov&amp;esheet=54540475&amp;newsitemid=20260521314535&amp;lan=en-US&amp;anchor=www.SEC.gov&amp;index=4&amp;md5=03b3d913ed2e4ebe18ad3e09da948b92" shape="rect">www.SEC.gov</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260521314535r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260521314535/en/" rel="nofollow">https://www.businesswire.com/news/home/20260521314535/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">For more information, please contact:</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Christine Chiou / Cyan Liu
<br xmlns="http://www.w3.org/1999/xhtml"></br>+1 (917) 886-6929 / +86 195 3130 8895
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:christine.chiou1@zailaboratory.com" shape="rect">christine.chiou1@zailaboratory.com</a> / <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:cyan.liu@zailaboratory.com" shape="rect">cyan.liu@zailaboratory.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Shaun Maccoun / Xiaoyu Chen
<br xmlns="http://www.w3.org/1999/xhtml"></br>+1 (857) 270-8854 / +86 185 0015 5011
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:shaun.maccoun@zailaboratory.com" shape="rect">shaun.maccoun@zailaboratory.com</a> / <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:xiaoyu.chen@zailaboratory.com" shape="rect">xiaoyu.chen@zailaboratory.com</a>

</p>

Zai Lab has announced the departure of its President and COO to enhance operational performance. The company plans multiple clinical data readouts in 2026 for investigational therapies, which could significantly impact stock performance as they approach potential launches and approvals.

Zai Lab Announces Changes to Senior Leadership Team

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News